Oncotarget

Research Papers:

Tumor SOCS3 methylation status predicts the treatment response to TACE and prognosis in HCC patients

Bei-Ge Jiang, Neng Wang, Jian Huang, Yuan Yang, Liang-Liang Sun, Ze-Ya Pan and Wei-Ping Zhou _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:28621-28627. https://doi.org/10.18632/oncotarget.16157

Metrics: PDF 930 views  |   HTML 1512 views  |   ?  


Abstract

Bei-Ge Jiang1,*, Neng Wang1,*, Jian Huang1,*, Yuan Yang1, Liang-Liang Sun2, Ze-Ya Pan1, Wei-Ping Zhou1

1Department of Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P.R. China

2Department of Endocrinology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, P.R. China

*These authors contribute equally to this work

Correspondence to:

Wei-Ping Zhou, email: ehphwp@126.com

Ze-Ya Pan, email: 378834858@qq.com

Liang-Liang Sun, email: sun_lliang@aliyun.com

Keywords: suppressor of cytokine signaling, transarterial chemoembolization, methylation, prognosis

Received: September 30, 2016     Accepted: January 24, 2017     Published: March 13, 2017

ABSTRACT

Background: Suppressor of cytokine signaling (SOCS) 1 and 3 methylation have been associated with clinical features and outcomes of cancer patients. However, their roles in determining the treatment response to transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) remain unknown.

Results: We found that presence of SOCS3 methylation is significantly associated with the major clinical features of HCC patients, including tumor stage, lymph node and vascular invasion. Of note, we observed that the presence of SOCS3 methylation is closely related to TACE response. In prognosis analyses, HCC patients with SOCS3 methylation presence have a poorer prognosis indicated by lower 3-, and 5-year survival rates and shorter mean survival period, than those without. Multivariate COX analysis confirms the prognostic role of the presence of SOCS3 methylation in HCC patients receiving TACE treatment.

Materials and Methods: A total of 246 HCC patients receiving TACE were enrolled in this study. Tumor samples was obtained from echo-guided fine needle aspiration and genomic DNA from tumor samples was purified. SOCS1 and SOCS3 methylation status were detected using methylation-specific polymerase chain reaction. The treatment responses to TACE of patients were evaluated after procedure and all patients were followed for prognosis analysis.

Conclusions: This finding suggests that the presence of SOCS3 methylation is a marker to predict treatment response and prognosis in HCC patients receiving TACE therapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16157